276 related articles for article (PubMed ID: 35831793)
1. Barriers and facilitators for therapeutic drug monitoring of beta-lactams and ciprofloxacin in the ICU: a nationwide cross-sectional study.
Ewoldt TMJ; Abdulla A; van den Broek P; Hunfeld N; Bahmany S; Muller AE; Gommers D; Polinder S; Endeman H; Spronk I; Koch BCP
BMC Infect Dis; 2022 Jul; 22(1):611. PubMed ID: 35831793
[TBL] [Abstract][Full Text] [Related]
2. Barriers and Facilitators in the Clinical Implementation of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: A Critical Review.
Abdulla A; van den Broek P; Ewoldt TMJ; Muller AE; Endeman H; Koch BCP
Ther Drug Monit; 2022 Feb; 44(1):112-120. PubMed ID: 34798631
[TBL] [Abstract][Full Text] [Related]
3. The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial.
Abdulla A; Ewoldt TMJ; Hunfeld NGM; Muller AE; Rietdijk WJR; Polinder S; van Gelder T; Endeman H; Koch BCP
BMC Infect Dis; 2020 Jan; 20(1):57. PubMed ID: 31952493
[TBL] [Abstract][Full Text] [Related]
4. The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for β-lactam administration and therapeutic drug monitoring among critically ill patients in France.
Charmillon A; Novy E; Agrinier N; Leone M; Kimmoun A; Levy B; Demoré B; Dellamonica J; Pulcini C
Clin Microbiol Infect; 2016 Jul; 22(7):625-31. PubMed ID: 27145210
[TBL] [Abstract][Full Text] [Related]
5. An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units.
Wong G; Brinkman A; Benefield RJ; Carlier M; De Waele JJ; El Helali N; Frey O; Harbarth S; Huttner A; McWhinney B; Misset B; Pea F; Preisenberger J; Roberts MS; Robertson TA; Roehr A; Sime FB; Taccone FS; Ungerer JP; Lipman J; Roberts JA
J Antimicrob Chemother; 2014 May; 69(5):1416-23. PubMed ID: 24443514
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: Availability, performance and barriers to implementation.
Sandaradura I; Alffenaar JW; Cotta MO; Daveson K; Day RO; Van Hal S; Lau C; Marriott DJE; Penm J; Roberts JA; Tabah A; Williams P; Imani S
Br J Clin Pharmacol; 2022 Feb; 88(2):669-679. PubMed ID: 34289135
[TBL] [Abstract][Full Text] [Related]
7. Assessment of current practice for β-lactam therapeutic drug monitoring in French ICUs in 2021: a nationwide cross-sectional survey.
Tritscher P; Delannoy M; Agrinier N; Charmillon A; Degand N; Dellamonica J; Roger C; Leone M; Scala-Bertola J; Novy E
J Antimicrob Chemother; 2022 Sep; 77(10):2650-2657. PubMed ID: 36059108
[TBL] [Abstract][Full Text] [Related]
8. Implementation Strategies Addressing Stakeholder-Perceived Barriers and Enablers to the Establishment of a Beta-Lactam Antibiotic Therapeutic Drug Monitoring Program: A Qualitative Analysis.
Pai Mangalore R; Udy AA; Peel TN; Peleg AY; Ayton D
Ther Drug Monit; 2024 Jun; 46(3):351-362. PubMed ID: 38018820
[TBL] [Abstract][Full Text] [Related]
9. Implementation of a β-lactam therapeutic drug monitoring program: Experience from a large academic medical center.
Venugopalan V; Hamza M; Santevecchi B; DeSear K; Cherabuddi K; Peloquin CA; Alshaer MH
Am J Health Syst Pharm; 2022 Sep; 79(18):1586-1591. PubMed ID: 35704702
[TBL] [Abstract][Full Text] [Related]
10. Why is the Implementation of Beta-Lactam Therapeutic Drug Monitoring for the Critically Ill Falling Short? A Multicenter Mixed-Methods Study.
Barreto EF; Chitre PN; Pine KH; Shepel KK; Rule AD; Alshaer MH; Abdul Aziz MH; Roberts JA; Scheetz MH; Ausman SE; Moreland-Head LN; Rivera CG; Jannetto PJ; Mara KC; Boehmer KR
Ther Drug Monit; 2023 Aug; 45(4):508-518. PubMed ID: 37076424
[TBL] [Abstract][Full Text] [Related]
11. Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy.
Economou CJP; Wong G; McWhinney B; Ungerer JPJ; Lipman J; Roberts JA
Int J Antimicrob Agents; 2017 May; 49(5):589-594. PubMed ID: 28341612
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of β-lactam therapeutic drug monitoring among US health systems with postgraduate year 2 infectious diseases pharmacy residency programs.
Chen C; Seabury RW; Steele JM; Parsels KA; Darko W; Miller CD; Kufel WD
Am J Health Syst Pharm; 2022 Jul; 79(15):1273-1280. PubMed ID: 35439284
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of β-lactam antibiotics in the ICU.
Dhaese S; Van Vooren S; Boelens J; De Waele J
Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1155-1164. PubMed ID: 32597263
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring to personalize dosing of imatinib, sunitinib, and pazopanib: A mixed methods study on barriers and facilitators.
Westerdijk K; Steeghs N; Tacke CSJ; van der Graaf WTA; van Erp NP; van Oortmerssen G; Hermens RPMG; Desar IME;
Cancer Med; 2023 Nov; 12(22):21041-21056. PubMed ID: 37902257
[TBL] [Abstract][Full Text] [Related]
15. Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial.
Ewoldt TMJ; Abdulla A; Rietdijk WJR; Muller AE; de Winter BCM; Hunfeld NGM; Purmer IM; van Vliet P; Wils EJ; Haringman J; Draisma A; Rijpstra TA; Karakus A; Gommers D; Endeman H; Koch BCP
Intensive Care Med; 2022 Dec; 48(12):1760-1771. PubMed ID: 36350354
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper
Abdul-Aziz MH; Alffenaar JC; Bassetti M; Bracht H; Dimopoulos G; Marriott D; Neely MN; Paiva JA; Pea F; Sjovall F; Timsit JF; Udy AA; Wicha SG; Zeitlinger M; De Waele JJ; Roberts JA; ; ; ;
Intensive Care Med; 2020 Jun; 46(6):1127-1153. PubMed ID: 32383061
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections?
Muller AE; Huttner B; Huttner A
Drugs; 2018 Mar; 78(4):439-451. PubMed ID: 29476349
[TBL] [Abstract][Full Text] [Related]
18. The clinical application of beta-lactam antibiotic therapeutic drug monitoring in the critical care setting.
Pai Mangalore R; Peel TN; Udy AA; Peleg AY
J Antimicrob Chemother; 2023 Oct; 78(10):2395-2405. PubMed ID: 37466209
[TBL] [Abstract][Full Text] [Related]
19. The ONTAI study - a survey on antimicrobial dosing and the practice of therapeutic drug monitoring in German intensive care units.
Liebchen U; Paal M; Scharf C; Schroeder I; Grabein B; Zander J; Siebers C; Zoller M
J Crit Care; 2020 Dec; 60():260-266. PubMed ID: 32932111
[TBL] [Abstract][Full Text] [Related]
20. Study protocol for ADAPT-TDM: A beta-lactam antibiotic Dose AdaPtation feasibility randomised controlled Trial using Therapeutic Drug Monitoring.
Pai Mangalore R; Chai MG; Pope J; Lee SJ; Padiglione A; Diehl A; Roberts L; Sim K; Rawson-Harris P; Wicha S; Schneider HG; Peel TN; Jenney A; Ayton D; Peleg AY; Udy AA
BMJ Open; 2024 Jul; 14(6):e083635. PubMed ID: 38951004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
